Cytoxan Articles
Coulter Pharmaceutical On Road To Success
19 March 1998
Asta Comes Through Tough Year, Looks To Expansion
4 March 1998
Genentech Progress With Breast Cancer Antibody
29 December 1998
FDA Panel Backs New Use For Intron A
23 October 1997
New Data With SB's Hycamtin In SCLC
22 August 1997
Genetics Institute's Neumega Backed By FDA Panel
30 July 1997
The Liposome Company: Focusing On Oncology
21 July 1997
Liposome Company's ARDS Drug Fails At Ph III
8 July 1997
Chemo Plus Tamoxifen More Effective
30 May 1997
Medarex' Promising Cancer Products
16 December 1996
IDEC Non-Hodgkin's Lymphoma Antibody Clears Phase III Trials
16 December 1996
Taxol Cleared For First-Line Use In Ovarian Cancer
28 October 1996
Australia Approves US Bioscience's Ethyol
16 September 1996
Ethyol Indications Extended
19 August 1996
Using BMT To Cure Autoimmunity
3 June 1996
Biomira's Cancer Vaccine Improves Survival
19 February 1996
Docetaxel Shows Efficacy In Ovarian Cancer
5 February 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Taxol Improves Survival In Ovarian Cancer Patients
15 January 1996
Biomira's Theratope Cancer Vaccine
18 December 1995
Phase II Study of IDEC Anticancer Antibody
13 November 1995
Sandoz MDR Drug Shows Promise In Early Trials
13 November 1995
ImmunoGen's Cancer Antibody
25 September 1995
...And US Bioscience's Ethyol
19 June 1995
Cytoxan Death Link
17 April 1995
First Approval For Ethyol, But FDA Panel Says No
19 December 1994
Taxotere Not Recommended For Approval In USA
19 December 1994
Pfizer Starts Ph III Trials Of TLC-D99
19 December 1994
Docetaxel Approved In First Market
12 December 1994
First Reports On Glaxo's Antiemetic Follow-up Drug
5 December 1994
Schering Launches Fludara In UK
31 October 1994
1st Cytoprotectant Set For EU Approval
3 October 1994
IND For CTI's Novel Cancer Drug In 1995?
26 September 1994
TAXOL SHOULD ONLY USED IN TRIALS, SAYS D&TB
27 June 1994
ENCOURAGING DATA FROM ETHYOL TRIAL
30 May 1994
REPLIGEN REVEALS AM285 DATA
18 April 1994
US BIO'S HEXALEN IN OVARIAN CANCER
11 April 1994
B-MS LAUNCHES TAXOL IN UK
17 January 1994
PHASE III DATA ON US BIO'S ETHYOL
29 November 1993
GLAXO'S DEFENDS ONDANSETRON ROLE
29 November 1993
TAXOL REVEALS FURTHER POTENTIAL
25 October 1993
PROSPECTS FOR A CANCER VACCINE: MUCIN EPITOPES
11 October 1993
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
ASCO STUDY SUPPORTS FIRST-LINE TAXOL
31 May 1993
FIRST RECOMBINANT STEM CELL FACTOR TRIALS
24 May 1993
GLAXO COMPROMISES OVER ONDANSETRON PATENT
26 April 1993
FDA C'TTEE TURNS DOWN SCIOS NOVA'S PERGAMID NDA
8 March 1993
US FINDS ETHYOL NDA "UNACCEPTABLE"
8 June 1992
APPROVAL SETBACK FOR US BIOSCIENCE
10 February 1992
CHEMOTHERAPY STUDY
3 February 1992
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
